PRESS RELEASE

Q4 2023 — Press release

Q4 2023PDF · 21 pages1.1 MB
Media contact:
Tesia Williams
media-relations@its.jnj.com
Investor contact:
Jessica Moore
investor-relations@its.jnj.com
For immediate release
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
• 2023 Fourth-Quarter reported sales growth of 7.3% to $21.4 Billion with operational growth of 7.2%* and
adjusted operational growth of 5.7%*. Operational growth excluding COVID-19 Vaccine of 10.9%*
• 2023 Fourth-Quarter Earnings per share (EPS) of $1.70 increasing 39.3% and adjusted EPS of $2.29
increasing by 11.7%*
• 2023 Full-Year reported sales growth of 6.5% to $85.2 Billion with operational growth of 7.4%* and
adjusted operational growth of 5.9%*. Operational growth excluding COVID-19 Vaccine of 9.0%*
• 2023 Full-Year EPS of $5.20 decreasing 15.3% due to a special one-time charge in the First-Quarter, and
adjusted EPS of $9.92 increasing by 11.1%*
• Company re-confirms guidance for 2024 with operational sales5 growth of 5.0% - 6.0%* and adjusted
operational EPS of $10.55 - $10.75, reflecting growth of 7.4%* at the mid-point
New Brunswick, N.J. (January 23, 2024) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter
and full year 2023. “Johnson & Johnson’s full year 2023 results reflect the breadth and competitiveness of our business and
our relentless focus on delivering for patients,” said Joaquin Duato, Chairman and Chief Executive Officer. “We have entered
2024 from a position of strength, and I am confident in our ability to lead the next wave of health innovation.”
Unless otherwise noted, the financial results and earnings guidance included below reflect the continuing operations of
Johnson & Johnson.
Overall Financial Results
Q4 Full Year
($ in Millions, except EPS) 2023 2022 % Change 2023 2022 % Change
Reported Sales $21,395 $19,939 7.3% $85,159 $79,990 6.5%
Net Earnings $4,132 $3,227 28.0% $13,326 $16,370 (18.6)%
EPS (diluted) $1.70 $1.22 39.3% $5.20 $6.14 (15.3)%
Q4 Full Year
Non-GAAP* ($ in Millions, except EPS) 2023 2022 % Change 2023 2022 % Change
Operational Sales1,2 7.2% 7.4%
Adjusted Operational Sales1,3 5.7% 5.9%
Adjusted Net Earnings1,4 $5,562 $5,432 2.4% $25,409 $23,796 6.8%
Adjusted EPS (diluted)1,4 $2.29 $2.05 11.7% $9.92 $8.93 11.1%
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
5 Excludes COVID-19 Vaccine
Note: Values may have been rounded

-- 1 of 21 --

Regional Sales Results
Q4 % Change
($ in Millions) 2023 2022 Reported Operational1,2 Currency Adjusted
Operational1,3
U.S. $12,009 $10,820 11.0% 11.0 - 8.8
International 9,386 9,119 2.9 2.7 0.2 2.1
Worldwide $21,395 $19,939 7.3% 7.2 0.1 5.7
Full Year % Change
($ in Millions) 2023 2022 Reported Operational1,2 Currency Adjusted
Operational1,3
U.S. $46,444 $41,981 10.6% 10.6 - 8.2
International 38,715 38,009 1.9 3.8 (1.9) 3.4
Worldwide $85,159 $79,990 6.5% 7.4 (0.9) 5.9
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: Values may have been rounded
Segment Sales Results
Q4 % Change
($ in Millions) 2023 2022 Reported Operational1,2 Currency Adjusted
Operational1,3
Innovative Medicine $13,722 $13,163 4.2% 4.0 0.2 4.0
MedTech 7,673 6,776 13.3 13.4 (0.1) 9.1
Worldwide $21,395 $19,939 7.3% 7.2 0.1 5.7
Full Year % Change
($ in Millions) 2023 2022 Reported Operational1,2 Currency Adjusted
Operational1,3
Innovative Medicine $54,759 $52,563 4.2% 4.8 (0.6) 4.9
MedTech 30,400 27,427 10.8 12.4 (1.6) 7.8
Worldwide $85,159 $79,990 6.5% 7.4 (0.9) 5.9
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: The Innovative Medicine segment was previously referred to as the Pharmaceutical segment
Values may have been rounded
Full Year 2023 Segment Commentary:
Operational sales* reflected below excludes the impact of translational currency. Adjusted operational sales* reflected below
excludes the net impact of acquisitions and divestitures and translational currency.
Innovative Medicine
Innovative Medicine worldwide operational sales, excluding the COVID-19 Vaccine, grew 7.2%*. Growth was driven by
DARZALEX (daratumumab), ERLEADA (apalutamide), TECVAYLI (teclistamab-cqyv) in Other Oncology, and CARVYKTI
(ciltacabtagene autoleucel) in Oncology, STELARA (ustekinumab) and TREMFYA (guselkumab) in Immunology, and
SPRAVATO (esketamine) in Neuroscience. Growth was partially offset by ZYTIGA (abiraterone acetate) and IMBRUVICA

-- 2 of 21 --

(ibrutinib) in Oncology, and REMICADE (infliximab) in Immunology. Including the COVID-19 Vaccine, Innovative Medicine
worldwide operational sales grew 4.8%*.
MedTech
MedTech worldwide operational sales grew 12.4%*, with the acquisition of Abiomed contributing 4.7%. MedTech worldwide
adjusted operational sales grew 7.8%*, driven primarily by electrophysiology products in Interventional Solutions, contact
lenses in Vision, wound closure products in General Surgery, and biosurgery in Advanced Surgery.
Notable New Announcements in the Quarter:
The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the
Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and
Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from
Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the
Investor Relations section of the company’s website at News Releases, as well as Innovative Medicine, MedTech,
www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LLTManagementInformation.com.
Regulatory
U.S. Food and Drug Administration Grants Full Approval for BALVERSA to Treat Locally
Advanced or Metastatic Bladder Cancer with Select Genetic Alterations1
Press
Release
Biosense Webster Announces Regulatory Approval of VARIPULSE Pulsed Field Ablation (PFA)
Platform in Japan1
Press
Release
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking
Approval of Lazertinib, in combination with RYBREVANT (amivantamab), for the First-Line
Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Press
Release
Johnson & Johnson Submits Supplemental Biologics License Application and New Drug Application
to U.S. FDA Seeking Approval of RYBREVANT (amivantamab-vmjw) Plus Lazertinib for the
Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
Press
Release
Johnson & Johnson’s Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy
Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer
Press
Release
Janssen Submits Application to the European Medicines Agency for RYBREVANT (amivantamab)
in Combination with Chemotherapy for the Treatment of Adult Patients with Advanced EGFR-
Mutated Non-Small Cell Lung Cancer After Failure of Prior Therapy
Press
Release
Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of
RYBREVANT (amivantamab-vmjw) Plus Chemotherapy for the Treatment of Patients with EGFR-
Mutated Non-Small Cell Lung Cancer Who Progressed on or after Osimertinib
Press
Release
MONARCH Platform for Bronchoscopy Receives Regulatory License for China Press
Release
Data Release
Johnson & Johnson highlights its preeminent leadership in hematology through differentiated blood
cancer portfolio and pipeline with new clinical and real-world data at ASH
Press
Release
New Real-World Data Show TREMFYA (guselkumab) Was Associated With Clinically Meaningful
Improvements in Patient-Reported Outcomes for Adults Living With Active Psoriatic Arthritis
Press
Release
Phase 2 Nipocalimab Data Establish Proof of Mechanism in Adults Living with Moderate to Severe
Rheumatoid Arthritis, Supporting its Progression into a Combination Study
Press
Release
New Biosense Webster QDOT MICRO Catheter Data Demonstrate Very High-Power, Short-
Duration Ablations Improved Quality of Life and Reduced Healthcare Utilization for AFib Patients
Press
Release
New Phase 3 TREMFYA (guselkumab) Results in Ulcerative Colitis Show a 77 Percent Overall
Clinical Response Rate and Early Symptom Improvement
Press
Release
Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with
Transformative Data Planned for Presentation at ESMO
Press
Release
Product Launch Ethicon Introduces ETHIZIA Hemostatic Sealing Patch, Clinically Proven to Stop Disruptive
Bleeding
Press
Release
Other
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to
Transform the Treatment of Cancer1
Press
Release
Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise
Business Review
Press
Release

-- 3 of 21 --

Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its
Board of Directors
Press
Release
Johnson & Johnson MedTech Acquires Laminar, Inc. Press
Release
Johnson & Johnson MedTech Provides Details and Timeline for General Surgery Robot Press
Release
Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice
President, Worldwide Chairman of MedTech
Press
Release
1 Subsequent to the quarter
Full-Year 2024 Guidance:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable
to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related
expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend
on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
($ in Billions, except EPS) January 2024 December 2023
Adjusted Operational Sales1,2,5
Change vs. Prior Year / Mid-point 5.0% – 6.0% / 5.5%
Operational Sales2,5/ Mid-point
Change vs. Prior Year / Mid-point
$88.2B – $89.0B / $88.6B
5.0% – 6.0% / 5.5% 5.0% – 6.0% / 5.5%
Estimated Reported Sales3,5/ Mid-point
Change vs. Prior Year / Mid-point
$87.8B – $88.6B / $88.2B
4.5% – 5.5% / 5.0%
Adjusted Operational EPS (Diluted)2,4/ Mid-point
Change vs. Prior Year / Mid-point
$10.55 – $10.75 / $10.65
6.4% – 8.4% / 7.4%
$10.55 – $10.75 / $10.65
7.3% Mid-point
Adjusted EPS (Diluted)3,4 / Mid-point
Change vs. Prior Year / Mid-point
$10.55 – $10.75 / $10.65
6.4% – 8.4% / 7.4%
Average Shares Outstanding (Diluted)6 ~2,435 million
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: January 2024 = $1.09 and December 2023 = $1.09 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
5 Excludes COVID-19 Vaccine
6 Full Year 2024 Projected Average Shares Outstanding (Diluted) reflects impact from the Kenvue exchange offer
Note: Percentages may have been rounded
Other modeling considerations will be provided on the webcast.
Webcast Information:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m.,
Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting

-- 4 of 21 --

the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast
in the Investor Relations section of the company's website at events-and-presentations.
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build
a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive,
and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to
innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and
profoundly impact health for humanity. Learn more at https://www.jnj.com/.
Non-GAAP Financial Measures:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth”
excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”,
“adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax
intangible amortization expense and special items, are non-GAAP financial measures and should not be considered
replacements for, and should be read together with, the most comparable GAAP financial measures. Except for
guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP
financial measures can be found in the accompanying financial schedules of the earnings release and the Investor
Relations section of the company's website at quarterly results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at
quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of
earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information
on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected
compounds in late stage development and a copy of today’s earnings call presentation can also be found in the
Investor Relations section of the company's website at quarterly results.
Note to Investors Concerning Forward-Looking Statements:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of
1995 regarding, among other things: future operating and financial performance, product development, and market
position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These
statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or
unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of
Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and
currency exchange rate fluctuations; competition, including technological advances, new products and patents attained
by competitors; challenges inherent in new product research and development, including uncertainty of clinical success
and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to
patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including
restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally
or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action;
significant adverse litigation or government action, including related to product liability claims; changes to applicable
laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment;
changes in behavior and spending patterns of purchasers of health care products and services; financial instability of
international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by
government agencies; the Company’s ability to realize the anticipated benefits from the separation of the Company’s
Consumer Health business; and the New Consumer Health Company’s ability to succeed as a standalone publicly
traded company. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson
& Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned
“Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s
subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies
of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-
looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of new information or future events or developments.

-- 5 of 21 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2023 	2022 	Total 	Operations 	Currency 	2023 	2022 	Total 	Operations 	Currency
Sales to customers by
segment of business
Innovative Medicine (1,2)
U.S. 	8,079 	7,375 	9.5 	9.5 	- 	31,169 	28,604 	9.0 	9.0 	-
International 	5,643 	5,788 	(2.5) 	(3.1) 	0.6 	23,590 	23,959 	(1.5) 	(0.2) 	(1.3)
13,722 	13,163 	4.2 	4.0 	0.2 	54,759 	52,563 	4.2 	4.8 	(0.6)
Innovative Medicine excluding COVID-19 Vaccine (1,2)
U.S. 	8,079 	7,375 	9.5 	9.5 	- 	31,169 	28,484 	9.4 	9.4 	-
International 	5,599 	5,099 	9.8 	9.4 	0.4 	22,473 	21,900 	2.6 	4.3 	(1.7)
13,678 	12,474 	9.7 	9.5 	0.2 	53,642 	50,384 	6.5 	7.2 	(0.7)
MedTech
U.S. 	3,930 	3,445 	14.1 	14.1 	- 	15,275 	13,377 	14.2 	14.2 	-
International 	3,743 	3,331 	12.4 	12.8 	(0.4) 	15,125 	14,050 	7.7 	10.6 	(2.9)
7,673 	6,776 	13.3 	13.4 	(0.1) 	30,400 	27,427 	10.8 	12.4 	(1.6)
U.S. 	12,009 	10,820 	11.0 	11.0 	- 	46,444 	41,981 	10.6 	10.6 	-
International 	9,386 	9,119 	2.9 	2.7 	0.2 	38,715 	38,009 	1.9 	3.8 	(1.9)
Worldwide 	21,395 	19,939 	7.3 	7.2 	0.1 	85,159 	79,990 	6.5 	7.4 	(0.9)
U.S. 	12,009 	10,820 	11.0 	11.0 	- 	46,444 	41,861 	10.9 	10.9 	-
International 	9,342 	8,430 	10.8 	10.7 	0.1 	37,598 	35,950 	4.6 	6.7 	(2.1)
Worldwide excluding COVID-19 Vaccine (1)	
21,351	$ 	19,250 	10.9 % 	10.9 	0.0 	84,042	$ 	77,811 	8.0 % 	9.0 	(1.0)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales reconciliation schedule
(2) Previously referred to as Pharmaceutical
FOURTH QUARTER 	TWELVE MONTHS
Percent Change

-- 6 of 21 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2023 	2022 	Total 	Operations 	Currency 	2023 	2022 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	12,009	$ 	10,820 	11.0 % 	11.0 	- 	46,444	$ 	41,981 	10.6 % 	10.6 	-
Europe 	4,962 	5,124 	(3.2) 	(5.8) 	2.6 	20,410 	20,664 	(1.2) 	(2.2) 	1.0
Western Hemisphere excluding U.S. 	1,166 	1,024 	14.0 	18.1 	(4.1) 	4,549 	4,108 	10.7 	15.8 	(5.1)
Asia-Pacific, Africa 	3,258 	2,971 	9.7 	12.1 	(2.4) 	13,756 	13,237 	3.9 	9.5 	(5.6)
International 	9,386 	9,119 	2.9 	2.7 	0.2 	38,715 	38,009 	1.9 	3.8 	(1.9)
Worldwide 	21,395	$ 	19,939 	7.3 % 	7.2 	0.1 	85,159	$ 	79,990 	6.5 % 	7.4 	(0.9)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FOURTH QUARTER 	TWELVE MONTHS
Percent Change

-- 7 of 21 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	21,395	$ 	100.0 	19,939	$ 	100.0 	7.3
Cost of products sold 	6,798 	31.8 	6,084 	30.5 	11.7
Gross Profit 	14,597 	68.2 	13,855 	69.5 	5.4
Selling, marketing and administrative expenses 	5,810 	27.1 	5,339 	26.8 	8.8
Research and development expense 	4,480 	20.9 	3,710 	18.6 	20.8
In-process research and development impairments 	58 	0.3 	173 	0.8
Interest (income) expense, net 	(212) 	(1.0) 	(77) 	(0.4)
Other (income) expense, net 	(421) 	(2.0) 	795 	4.0
Restructuring 	56 	0.3 	75 	0.4
Earnings before provision for taxes on income 	4,826 	22.6 	3,840 	19.3 	25.7
Provision for taxes on income 	694 	3.3 	613 	3.1 	13.2
Net earnings from Continuing Operations 	4,132	$ 	19.3 	3,227	$ 	16.2 	28.0
Net earnings/(loss) from Discontinued Operations, net of tax 	(83) 	293
Net earnings 	4,049	$ 	3,520	$
Net earnings per share (Diluted) from Continuing Operations 	1.70	$ 	1.22	$ 	39.3
Net earnings/(loss) per share (Basic/Diluted) from Discontinued Operations* 	(0.03)	$ 	0.11	$
Average shares outstanding (Diluted) 	2,430.7 	2,650.1
Effective tax rate from Continuing Operations 	14.4 % 	16.0 %
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from Continuing Operations 	6,237	$ 	29.2 	6,482	$ 	32.5 	(3.8)
Net earnings from Continuing Operations 	5,562	$ 	26.0 	5,432	$ 	27.2 	2.4
Net earnings per share (Diluted) from Continuing Operations 	2.29	$ 	2.05	$ 	11.7
Effective tax rate from Continuing Operations 	10.8 % 	16.2 %
* Basic shares of 2,407.2 are used to calculate loss per share in the fourth quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive.
(1) See Reconciliation of Non-GAAP Financial Measures.
FOURTH QUARTER
2023 	2022

-- 8 of 21 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	85,159	$ 	100.0 	79,990	$ 	100.0 	6.5
Cost of products sold 	26,553 	31.2 	24,596 	30.7 	8.0
Gross Profit 	58,606 	68.8 	55,394 	69.3 	5.8
Selling, marketing and administrative expenses 	21,512 	25.2 	20,246 	25.3 	6.3
Research and development expense 	15,085 	17.7 	14,135 	17.7 	6.7
In-process research and development impairments 	313 	0.4 	783 	1.0
Interest (income) expense, net 	(489) 	(0.6) 	(214) 	(0.3)
Other (income) expense, net 	6,634 	7.8 	810 	1.0
Restructuring 	489 	0.6 	275 	0.4
Earnings before provision for taxes on income 	15,062 	17.7 	19,359 	24.2 	(22.2)
Provision for taxes on income 	1,736 	2.1 	2,989 	3.7 	(41.9)
Net earnings from Continuing Operations 	13,326	$ 	15.6 	16,370	$ 	20.5 	(18.6)
Net earnings from Discontinued Operations, net of tax 	21,827 	1,571
Net earnings 	35,153	$ 	17,941	$
Net earnings per share (Diluted) from Continuing Operations 	5.20	$ 	6.14	$ 	(15.3)
Net earnings per share (Diluted) from Discontinued Operations 	8.52	$ 	0.59	$
Average shares outstanding (Diluted) 	2,560.4 	2,663.9
Effective tax rate from Continuing Operations 	11.5 % 	15.4 %
Adjusted earnings from continuing operations before provision for taxes and net earnings (1)
Earnings before provision for taxes on income from Continuing Operations 	29,811	$ 	35.0 	27,973	$ 	35.0 	6.6
Net earnings from Continuing Operations 	25,409	$ 	29.8 	23,796	$ 	29.7 	6.8
Net earnings per share (Diluted) from Continuing Operations 	9.92	$ 	8.93	$ 	11.1
Effective tax rate from Continuing Operations 	14.8 % 	14.9 %
(1) See Reconciliation of Non-GAAP Financial Measures.
TWELVE MONTHS
2023 	2022

-- 9 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2023 	2022 	2023 	2022
Net Earnings from Continuing Operations, after tax- as reported 	$4,132 	$3,227 	$13,326 	$16,370
Pre-tax Adjustments
Litigation related 	166 	262 	7,152 	866
Intangible Asset Amortization expense 	1,148 	977 	4,532 	3,944
COVID-19 Vaccine related costs 1 	10 	821 	663 	1,474
Restructuring related 2 	139 	119 	798 	372
Medical Device Regulation 3 	88 	88 	311 	296
Acquisition, integration and divestiture related 	237 	196 	339 	196
(Gains)/losses on securities 	(435) 	6 	641 	690
IPR&D impairments 	58 	173 	313 	783
Other 	- 	- 	- 	(7)
Tax Adjustments
Tax impact on special item adjustments 4 	75 	(394) 	(2,694) 	(1,294)
Tax legislation and other tax related 	(56) 	(43) 	28 	106
Adjusted Net Earnings from Continuing Operations, after tax 	$5,562 	$5,432 	$25,409 	$23,796
Average shares outstanding (Diluted) 	2,430.7 	2,650.1 	2,560.4 	2,663.9
Adjusted net earnings per share from Continuing Operations (Diluted) 	$2.29 	$2.05 	$9.92 	$8.93
Operational adjusted net earnings per share from Continuing Operations (Diluted) 	$2.28 	$9.89
Notes:
1
2
3
4
European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a
replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were
required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change
and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech
operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed
during 2024.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in
arriving at adjusted earnings.
Fourth Quarter 	Twelve Months Ended
In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus
on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D
program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program,
hepatitis and HIV development. The restructuring expenses of $55 million in the quarter ($479 million Q4 YTD) include the termination of partnered and
non-partnered program costs and asset impairments.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting
certain markets, product lines and distribution network arrangements. The restructuring expenses of $84 million in the quarter ($319 million Q4 YTD)
primarily includes inventory and instrument reserves related to the market and product exits.
COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required
clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments.

-- 10 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine 	MedTech 	Total
WW As Reported 	4.2% 	13.3% 	7.3%
U.S. 	9.5% 	14.1% 	11.0%
International 	(2.5)% 	12.4% 	2.9%
WW Currency 	0.2 	(0.1) 	0.1
U.S. 	- 	- 	-
International 	0.6 	(0.4) 	0.2
WW Operational 	4.0% 	13.4% 	7.2%
U.S. 	9.5% 	14.1% 	11.0%
International 	(3.1)% 	12.8% 	2.7%
Abiomed 	(4.5) 	(1.6)
U.S. 	(7.2) 	(2.3)
International 	(1.9) 	(0.7)
All Other Acquisitions and Divestitures 	0.0 	0.2 	0.1
U.S. 	0.0 	0.3 	0.1
International 	0.1 	0.1 	0.1
WW Adjusted Operational 	4.0% 	9.1% 	5.7%
U.S. 	9.5% 	7.2% 	8.8%
International 	(3.0)% 	11.0% 	2.1%
Adjusted Operational Sales Growth
FOURTH QUARTER 2023 ACTUAL vs. 2022 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 11 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine 	MedTech 	Total
WW As Reported 	4.2% 	10.8% 	6.5%
U.S. 	9.0% 	14.2% 	10.6%
International 	(1.5)% 	7.7% 	1.9%
WW Currency 	(0.6) 	(1.6) 	(0.9)
U.S. 	- 	- 	-
International 	(1.3) 	(2.9) 	(1.9)
WW Operational 	4.8% 	12.4% 	7.4%
U.S. 	9.0% 	14.2% 	10.6%
International 	(0.2)% 	10.6% 	3.8%
Abiomed 	(4.7) 	(1.6)
U.S. 	(7.7) 	(2.5)
International 	(1.7) 	(0.6)
All Other Acquisitions and Divestitures 	0.1 	0.1 	0.1
U.S. 	0.0 	0.1 	0.1
International 	0.2 	0.1 	0.2
WW Adjusted Operational 	4.9% 	7.8% 	5.9%
U.S. 	9.0% 	6.6% 	8.2%
International 	0.0% 	9.0% 	3.4%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
TWELVE MONTHS 2023 ACTUAL vs. 2022 ACTUAL
Segments

-- 12 of 21 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
INNOVATIVE MEDICINE SEGMENT (2,3,4) 	2023 	2022 	Reported Operational (1) Currency 	2023 	2022 	Reported Operational (1) Currency
IMMUNOLOGY
US 	3,033	$ 	2,805 	8.1% 	8.1% 	- 	11,539	$ 	11,036 	4.6% 	4.6% 	-
Intl 	1,562 	1,312 	19.0% 	17.7% 	1.3% 	6,513 	5,899 	10.4% 	12.0% 	-1.6%
WW 	4,595 	4,118 	11.6% 	11.2% 	0.4% 	18,052 	16,935 	6.6% 	7.1% 	-0.5%
REMICADE
US 	294 	318 	-7.4% 	-7.4% 	- 	1,143 	1,417 	-19.3% 	-19.3% 	-
US Exports (5) 	35 	41 	-15.1% 	-15.1% 	- 	147 	204 	-28.0% 	-28.0% 	-
Intl 	100 	116 	-13.4% 	-12.4% 	-1.0% 	549 	722 	-23.9% 	-21.3% 	-2.6%
WW 	429 	475 	-9.6% 	-9.4% 	-0.2% 	1,839 	2,343 	-21.5% 	-20.7% 	-0.8%
SIMPONI / SIMPONI ARIA
US 	258 	280 	-7.8% 	-7.8% 	- 	1,124 	1,166 	-3.6% 	-3.6% 	-
Intl 	244 	220 	10.1% 	11.8% 	-1.7% 	1,073 	1,017 	5.4% 	9.3% 	-3.9%
WW 	502 	501 	0.1% 	0.8% 	-0.7% 	2,197 	2,184 	0.6% 	2.4% 	-1.8%
STELARA
US 	1,786 	1,621 	10.1% 	10.1% 	- 	6,966 	6,388 	9.0% 	9.0% 	-
Intl 	967 	764 	26.4% 	23.9% 	2.5% 	3,892 	3,335 	16.7% 	17.4% 	-0.7%
WW 	2,753 	2,386 	15.3% 	14.5% 	0.8% 	10,858 	9,723 	11.7% 	11.9% 	-0.2%
TREMFYA
US 	657 	541 	21.6% 	21.6% 	- 	2,147 	1,844 	16.5% 	16.5% 	-
Intl 	252 	211 	19.4% 	17.8% 	1.6% 	999 	824 	21.2% 	22.4% 	-1.2%
WW 	910 	752 	21.0% 	20.5% 	0.5% 	3,147 	2,668 	17.9% 	18.3% 	-0.4%
OTHER IMMUNOLOGY
US 	2 	3 	-22.8% 	-22.8% 	- 	11 	17 	-33.8% 	-33.8% 	-
Intl 	0 	0 	- 	- 	- 	0 	0 	- 	- 	-
WW 	2 	3 	-22.8% 	-22.8% 	- 	11 	17 	-33.8% 	-33.8% 	-
INFECTIOUS DISEASES
US 	353 	414 	-14.6% 	-14.6% 	- 	1,500 	1,680 	-10.7% 	-10.7% 	-
Intl 	498 	1,127 	-55.8% 	-58.2% 	2.4% 	2,918 	3,769 	-22.6% 	-23.9% 	1.3%
WW 	852 	1,540 	-44.7% 	-46.5% 	1.8% 	4,418 	5,449 	-18.9% 	-19.8% 	0.9%
COVID-19 VACCINE
US 	0 	0 	- 	- 	- 	0 	120 	* 	* 	-
Intl 	44 	689 	-93.7% 	-95.2% 	1.5% 	1,117 	2,059 	-45.8% 	-47.2% 	1.4%
WW 	44 	689 	-93.7% 	-95.2% 	1.5% 	1,117 	2,179 	-48.8% 	-50.1% 	1.3%
EDURANT / rilpivirine
US 	9 	9 	-12.4% 	-12.4% 	- 	35 	36 	-3.7% 	-3.7% 	-
Intl 	299 	281 	6.4% 	1.5% 	4.9% 	1,115 	972 	14.8% 	12.1% 	2.7%
WW 	307 	290 	5.8% 	1.0% 	4.8% 	1,150 	1,008 	14.1% 	11.5% 	2.6%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	341 	398 	-14.4% 	-14.4% 	- 	1,446 	1,494 	-3.2% 	-3.2% 	-
Intl 	98 	95 	3.1% 	-0.8% 	3.9% 	408 	449 	-9.2% 	-10.4% 	1.2%
WW 	439 	493 	-11.0% 	-11.8% 	0.8% 	1,854 	1,943 	-4.6% 	-4.9% 	0.3%
OTHER INFECTIOUS DISEASES
US 	4 	6 	-30.4% 	-30.4% 	- 	19 	30 	-34.5% 	-34.5% 	-
Intl 	58 	61 	-5.6% 	-4.9% 	-0.7% 	278 	289 	-3.8% 	-0.4% 	-3.4%
WW 	62 	67 	-7.8% 	-7.1% 	-0.7% 	297 	318 	-6.7% 	-3.6% 	-3.1%
% Change	% Change

-- 13 of 21 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2023 	2022 	Reported Operational (1) Currency 	2023 	2022 	Reported Operational (1) Currency
NEUROSCIENCE
US 	1,022 	912 	12.1% 	12.1% 	- 	4,065 	3,570 	13.9% 	13.9% 	-
Intl 	780 	825 	-5.5% 	-2.0% 	-3.5% 	3,076 	3,323 	-7.5% 	-3.7% 	-3.8%
WW 	1,801 	1,737 	3.7% 	5.4% 	-1.7% 	7,140 	6,893 	3.6% 	5.4% 	-1.8%
CONCERTA / Methylphenidate
US 	39 	37 	5.7% 	5.7% 	- 	230 	151 	52.5% 	52.5% 	-
Intl 	142 	131 	7.9% 	9.2% 	-1.3% 	554 	493 	12.2% 	16.4% 	-4.2%
WW 	180 	168 	7.4% 	8.5% 	-1.1% 	783 	644 	21.6% 	24.9% 	-3.3%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	733 	678 	8.0% 	8.0% 	- 	2,897 	2,714 	6.7% 	6.7% 	-
Intl 	278 	329 	-15.5% 	-15.7% 	0.2% 	1,218 	1,426 	-14.6% 	-12.8% 	-1.8%
WW 	1,011 	1,008 	0.3% 	0.3% 	0.0% 	4,115 	4,140 	-0.6% 	0.0% 	-0.6%
SPRAVATO
US 	180 	105 	72.3% 	72.3% 	- 	589 	328 	79.7% 	79.7% 	-
Intl 	26 	14 	87.1% 	83.4% 	3.7% 	100 	46 	* 	* *
WW 	206 	119 	74.1% 	73.6% 	0.5% 	689 	374 	84.1% 	84.0% 	0.1%
OTHER NEUROSCIENCE
US 	71 	91 	-23.0% 	-23.0% 	- 	349 	376 	-7.3% 	-7.3% 	-
Intl 	334 	351 	-5.0% 	3.2% 	-8.2% 	1,204 	1,358 	-11.3% 	-5.4% 	-5.9%
WW 	404 	442 	-8.7% 	-2.3% 	-6.4% 	1,553 	1,734 	-10.4% 	-5.9% 	-4.5%
ONCOLOGY
US 	2,285 	1,857 	23.0% 	23.0% 	- 	8,462 	6,930 	22.1% 	22.1% 	-
Intl 	2,334 	2,069 	12.8% 	12.0% 	0.8% 	9,199 	9,052 	1.6% 	2.9% 	-1.3%
WW 	4,618 	3,927 	17.6% 	17.2% 	0.4% 	17,661 	15,983 	10.5% 	11.2% 	-0.7%
CARVYKTI
US 	145 	54 	* 	* 	- 	469 	133 	* 	* 	-
Intl 	13 	- 	* 	* 	- 	30 	- 	* 	* 	-
WW 	159 	54 	* 	* 	500 	133 	* 	* *
DARZALEX
US 	1,395 	1,139 	22.5% 	22.5% 	- 	5,277 	4,210 	25.4% 	25.4% 	-
Intl 	1,155 	944 	22.3% 	21.8% 	0.5% 	4,467 	3,767 	18.6% 	20.2% 	-1.6%
WW 	2,550 	2,083 	22.4% 	22.2% 	0.2% 	9,744 	7,977 	22.2% 	22.9% 	-0.7%
ERLEADA
US 	287 	275 	4.4% 	4.4% 	- 	1,065 	968 	10.0% 	10.0% 	-
Intl 	361 	266 	35.6% 	34.0% 	1.6% 	1,322 	913 	44.8% 	46.0% 	-1.2%
WW 	647 	541 	19.8% 	19.0% 	0.8% 	2,387 	1,881 	26.9% 	27.5% 	-0.6%
IMBRUVICA
US 	255 	318 	-19.8% 	-19.8% 	- 	1,051 	1,390 	-24.4% 	-24.4% 	-
Intl 	533 	547 	-2.6% 	-3.8% 	1.2% 	2,214 	2,394 	-7.5% 	-6.7% 	-0.8%
WW 	788 	866 	-8.9% 	-9.7% 	0.8% 	3,264 	3,784 	-13.7% 	-13.2% 	-0.5%
ZYTIGA / abiraterone acetate
US 	9 	20 	-52.0% 	-52.0% 	- 	50 	74 	-32.1% 	-32.1% 	-
Intl 	191 	250 	-23.6% 	-23.2% 	-0.4% 	837 	1,696 	-50.7% 	-49.1% 	-1.6%
WW 	201 	270 	-25.6% 	-25.3% 	-0.3% 	887 	1,770 	-49.9% 	-48.4% 	-1.5%
OTHER ONCOLOGY
US 	192 	52 	* 	* 	- 	549 	156 	* 	* 	-
Intl 	82 	63 	32.2% 	28.4% 	3.8% 	330 	283 	16.9% 	17.0% 	-0.1%
WW 	274 	114 	* 	* * 	879 	438 	* 	* *
% Change	% Change

-- 14 of 21 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2023 	2022 	Reported Operational (1) Currency 	2023 	2022 	Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 	733 	610 	20.2% 	20.2% 	- 	2,697 	2,346 	15.0% 	15.0% 	-
Intl 	282 	261 	8.6% 	10.9% 	-2.3% 	1,117 	1,071 	4.3% 	8.3% 	-4.0%
WW 	1,017 	870 	16.7% 	17.4% 	-0.7% 	3,815 	3,417 	11.6% 	12.9% 	-1.3%
OPSUMIT
US 	368 	305 	20.5% 	20.5% 	- 	1,292 	1,132 	14.1% 	14.1% 	-
Intl 	169 	156 	7.9% 	8.3% 	-0.4% 	681 	651 	4.6% 	7.2% 	-2.6%
WW 	536 	461 	16.2% 	16.3% 	-0.1% 	1,973 	1,783 	10.6% 	11.6% 	-1.0%
UPTRAVI
US 	348 	280 	24.3% 	24.3% 	- 	1,326 	1,104 	20.1% 	20.1% 	-
Intl 	70 	56 	26.4% 	31.4% 	-5.0% 	255 	218 	17.3% 	21.8% 	-4.5%
WW 	419 	336 	24.6% 	25.4% 	-0.8% 	1,582 	1,322 	19.7% 	20.4% 	-0.7%
OTHER PULMONARY HYPERTENSION
US 	18 	24 	-29.4% 	-29.4% 	- 	79 	110 	-28.6% 	-28.6% 	-
Intl 	45 	48 	-9.7% 	-3.9% 	-5.8% 	182 	202 	-10.3% 	-2.9% 	-7.4%
WW 	61 	73 	-16.2% 	-12.4% 	-3.8% 	260 	313 	-16.7% 	-12.0% 	-4.7%
CARDIOVASCULAR / METABOLISM / OTHER
US 	652 	776 	-15.9% 	-15.9% 	- 	2,906 	3,042 	-4.5% 	-4.5% 	-
Intl 	185 	194 	-4.7% 	-6.7% 	2.0% 	765 	845 	-9.4% 	-9.1% 	-0.3%
WW 	837 	971 	-13.7% 	-14.1% 	0.4% 	3,671 	3,887 	-5.5% 	-5.5% 	0.0%
XARELTO
US 	525 	667 	-21.2% 	-21.2% 	- 	2,365 	2,473 	-4.4% 	-4.4% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	525 	667 	-21.2% 	-21.2% 	- 	2,365 	2,473 	-4.4% 	-4.4% 	-
OTHER
US 	127 	110 	15.9% 	15.9% 	- 	541 	569 	-5.0% 	-5.0% 	-
Intl 	185 	194 	-4.7% 	-6.7% 	2.0% 	765 	845 	-9.4% 	-9.1% 	-0.3%
WW 	312 	304 	2.8% 	1.5% 	1.3% 	1,306 	1,414 	-7.6% 	-7.4% 	-0.2%
TOTAL INNOVATIVE MEDICINE
US 	8,079 	7,375 	9.5% 	9.5% 	- 	31,169 	28,604 	9.0% 	9.0% 	-
Intl 	5,643 	5,788 	-2.5% 	-3.1% 	0.6% 	23,590 	23,959 	-1.5% 	-0.2% 	-1.3%
WW 	13,722	$ 	13,163 	4.2% 	4.0% 	0.2% 	54,759	$ 	52,563 	4.2% 	4.8% 	-0.6%
See footnotes at end of schedule
% Change	% Change

-- 15 of 21 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
MEDTECH SEGMENT (2,3) 	2023 	2022 	Reported Operational (1) Currency 	2023 	2022 	Reported Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 	971	$ 	603 	61.0% 	61.0% 	- 	3,633	$ 	2,169 	67.5% 	67.5% 	-
Intl 	698 	495 	40.8% 	41.7% 	-0.9% 	2,717 	2,131 	27.5% 	31.7% 	-4.2%
WW 	1,669 	1,098 	51.9% 	52.3% 	-0.4% 	6,350 	4,300 	47.7% 	49.8% 	-2.1%
ELECTROPHYSIOLOGY
US 	667 	547 	22.0% 	22.0% 	- 	2,458 	2,036 	20.7% 	20.7% 	-
Intl 	572 	447 	28.0% 	29.0% 	-1.0% 	2,230 	1,901 	17.3% 	21.5% 	-4.2%
WW 	1,239 	994 	24.7% 	25.2% 	-0.5% 	4,688 	3,937 	19.1% 	21.1% 	-2.0%
ABIOMED
US 	276 	31 	* 	* 	- 	1,066 	31 	* 	* 	-
Intl 	64 	- 	* 	* 	- 	240 	- 	* 	* 	-
WW 	340 	31 	* 	* 	- 	1,306 	31 	* 	* 	-
OTHER INTERVENTIONAL SOLUTIONS
US 	28 	25 	8.8% 	8.8% 	- 	109 	102 	6.7% 	6.7% 	-
Intl 	61 	48 	26.5% 	27.1% 	-0.6% 	247 	230 	7.3% 	11.4% 	-4.1%
WW 	89 	73 	20.4% 	20.7% 	-0.3% 	356 	332 	7.1% 	9.9% 	-2.8%
ORTHOPAEDICS
US 	1,425 	1,385 	2.9% 	2.9% 	- 	5,525 	5,321 	3.8% 	3.8% 	-
Intl 	843 	763 	10.5% 	8.8% 	1.7% 	3,417 	3,267 	4.6% 	5.8% 	-1.2%
WW 	2,268 	2,148 	5.6% 	5.0% 	0.6% 	8,942 	8,587 	4.1% 	4.6% 	-0.5%
HIPS
US 	266 	250 	6.3% 	6.3% 	- 	996 	943 	5.6% 	5.6% 	-
Intl 	132 	135 	-2.0% 	-3.9% 	1.9% 	564 	571 	-1.2% 	-0.1% 	-1.1%
WW 	398 	385 	3.4% 	2.7% 	0.7% 	1,560 	1,514 	3.0% 	3.5% 	-0.5%
KNEES
US 	242 	231 	4.5% 	4.5% 	- 	896 	851 	5.3% 	5.3% 	-
Intl 	144 	122 	18.1% 	15.6% 	2.5% 	559 	508 	10.2% 	11.1% 	-0.9%
WW 	387 	354 	9.2% 	8.4% 	0.8% 	1,456 	1,359 	7.1% 	7.5% 	-0.4%
TRAUMA
US 	487 	470 	3.6% 	3.6% 	- 	1,949 	1,882 	3.6% 	3.6% 	-
Intl 	255 	240 	5.9% 	4.1% 	1.8% 	1,030 	989 	4.1% 	4.8% 	-0.7%
WW 	741 	710 	4.4% 	3.8% 	0.6% 	2,979 	2,871 	3.8% 	4.0% 	-0.2%
SPINE, SPORTS & OTHER
US 	430 	434 	-0.7% 	-0.7% 	- 	1,684 	1,645 	2.4% 	2.4% 	-
Intl 	311 	265 	17.5% 	16.5% 	1.0% 	1,263 	1,198 	5.4% 	7.3% 	-1.9%
WW 	742 	699 	6.2% 	5.8% 	0.4% 	2,947 	2,843 	3.7% 	4.5% 	-0.8%
% Change	% Change

-- 16 of 21 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2023 	2022 	Reported Operational (1) Currency 	2023 	2022 	Reported Operational (1) Currency
SURGERY
US 	1,047 	1,000 	4.6% 	4.6% 	- 	4,031 	3,897 	3.4% 	3.4% 	-
Intl 	1,484 	1,383 	7.2% 	7.8% 	-0.6% 	6,006 	5,793 	3.7% 	7.0% 	-3.3%
WW 	2,530 	2,384 	6.1% 	6.4% 	-0.3% 	10,037 	9,690 	3.6% 	5.5% 	-1.9%
ADVANCED
US 	468 	456 	2.5% 	2.5% 	- 	1,833 	1,784 	2.8% 	2.8% 	-
Intl 	698 	653 	7.0% 	7.2% 	-0.2% 	2,837 	2,785 	1.9% 	5.1% 	-3.2%
WW 	1,167 	1,109 	5.1% 	5.2% 	-0.1% 	4,671 	4,569 	2.2% 	4.2% 	-2.0%
GENERAL
US 	579 	544 	6.4% 	6.4% 	- 	2,198 	2,113 	4.0% 	4.0% 	-
Intl 	785 	731 	7.4% 	8.3% 	-0.9% 	3,168 	3,008 	5.3% 	8.7% 	-3.4%
WW 	1,364 	1,275 	7.0% 	7.5% 	-0.5% 	5,366 	5,121 	4.8% 	6.8% 	-2.0%
VISION
US 	487 	456 	6.8% 	6.8% 	- 	2,086 	1,990 	4.8% 	4.8% 	-
Intl 	721 	689 	4.6% 	6.4% 	-1.8% 	2,986 	2,859 	4.5% 	7.9% 	-3.4%
WW 	1,208 	1,145 	5.5% 	6.6% 	-1.1% 	5,072 	4,849 	4.6% 	6.6% 	-2.0%
CONTACT LENSES / OTHER
US 	374 	343 	8.9% 	8.9% 	- 	1,626 	1,522 	6.8% 	6.8% 	-
Intl 	508 	489 	4.2% 	7.2% 	-3.0% 	2,076 	2,022 	2.7% 	7.0% 	-4.3%
WW 	882 	831 	6.1% 	7.9% 	-1.8% 	3,702 	3,543 	4.5% 	6.9% 	-2.4%
SURGICAL
US 	114 	113 	0.4% 	0.4% 	- 	460 	468 	-1.8% 	-1.8% 	-
Intl 	212 	200 	5.6% 	4.7% 	0.9% 	910 	837 	8.6% 	10.0% 	-1.4%
WW 	326 	314 	3.7% 	3.1% 	0.6% 	1,370 	1,306 	4.9% 	5.8% 	-0.9%
TOTAL MEDTECH
US 	3,930 	3,445 	14.1% 	14.1% 	- 	15,275 	13,377 	14.2% 	14.2% 	-
Intl 	3,743 	3,331 	12.4% 	12.8% 	-0.4% 	15,125 	14,050 	7.7% 	10.6% 	-2.9%
WW 	7,673	$ 	6,776 	13.3% 	13.4% 	-0.1% 	30,400	$ 	27,427 	10.8% 	12.4% 	-1.6%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Previously referred to as Pharmaceutical
(5) Reported as U.S. sales
% Change
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely
% Change

-- 17 of 21 --

2023 	2022 	Total 	Operations Currency 	2023 	2022 	Total 	Operations Currency
Innovative Medicine
U.S. 	8,079	$ 	7,375 	9.5 % 	9.5 	- 	31,169	$ 	28,604 	9.0 % 	9.0 	-
International 	5,643 	5,788 	(2.5) 	(3.1) 	0.6 	23,590 	23,959 	(1.5) 	(0.2) 	(1.3)
Worldwide 	13,722 	13,163 	4.2 	4.0 	0.2 	54,759 	52,563 	4.2 	4.8 	(0.6)
COVID-19 Vaccine
U.S. 	- 	- 	- 	- 	- 	- 	120 	* 	* 	-
International 	44 	689 	(93.7) 	(95.2) 	1.5 	1,117 	2,059 	(45.8) 	(47.2) 	1.4
Worldwide 	44 	689 	(93.7) 	(95.2) 	1.5 	1,117 	2,179 	(48.8) 	(50.1) 	1.3
Innovative Medicine excluding COVID-19 Vaccine
U.S. 	8,079 	7,375 	9.5 	9.5 	- 	31,169 	28,484 	9.4 	9.4 	-
International 	5,599 	5,099 	9.8 	9.4 	0.4 	22,473 	21,900 	2.6 	4.3 	(1.7)
Worldwide 	13,678 	12,474 	9.7 	9.5 	0.2 	53,642 	50,384 	6.5 	7.2 	(0.7)
Worldwide
U.S. 	12,009 	10,820 	11.0 	11.0 	- 	46,444 	41,981 	10.6 	10.6 	-
International 	9,386 	9,119 	2.9 	2.7 	0.2 	38,715 	38,009 	1.9 	3.8 	(1.9)
Worldwide 	21,395 	19,939 	7.3 	7.2 	0.1 	85,159 	79,990 	6.5 	7.4 	(0.9)
COVID-19 Vaccine
U.S. 	- 	- 	- 	- 	- 	- 	120 	* 	* 	-
International 	44 	689 	(93.7) 	(95.2) 	1.5 	1,117 	2,059 	(45.8) 	(47.2) 	1.4
Worldwide 	44 	689 	(93.7) 	(95.2) 	1.5 	1,117 	2,179 	(48.8) 	(50.1) 	1.3
Worldwide
U.S. 	12,009 	10,820 	11.0 	11.0 	- 	46,444 	41,861 	10.9 	10.9 	-
International 	9,342 	8,430 	10.8 	10.7 	0.1 	37,598 	35,950 	4.6 	6.7 	(2.1)
Worldwide excluding COVID-19 Vaccine 	21,351	$ 	19,250 	10.9 % 	10.9 	- 	84,042	$ 	77,811 	8.0 % 	9.0 	(1.0)
Note: Columns and rows within tables may not add due to rounding
* Percentage greater than 100% or not meaningful
Supplemental Sales Reconciliation (Unaudited)
(Dollars in Millions)
FOURTH QUARTER 	TWELVE MONTHS
Percent Change 	Percent Change

-- 18 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022
Reported Income Before Tax by Segment From Continuing Operations $ 	4,238 	3,223 	404 	806 	184 	(189) 	4,826 	3,840
% to Sales 	30.9% 	24.5% 	5.3% 	11.9% 	0.9% 	-0.9% 	22.6% 	19.3%
Intangible asset amortization expense 	747 	717 	401 	260 	- 	- 	1,148 	977
In-process research and development impairments 	- 	173 	58 	- 	- 	- 	58 	173
Litigation related 	17 	76 	149 	136 	- 	50 	166 	262
Loss/(gain) on securities 	(112) 	23 	(59) 	(17) 	(264) 	- 	(435) 	6
Restructuring related 	55 	31 	84 	88 	- 	- 	139 	119
Acquisition, integration and divestiture related 	175 	(104) 	62 	300 	- 	- 	237 	196
Medical Device Regulation 	- 	- 	88 	88 	- 	- 	88 	88
COVID-19 Vaccine related costs 	10 	821 	- 	- 	- 	- 	10 	821
Adjusted Income Before Tax by Segment From Continuing Operations 	$ 	5,130 	4,960 	1,187 	1,661 	(80) 	(139) 	6,237 	6,482
% to Sales 	37.4% 	37.7% 	15.5% 	24.5% 	-0.4% 	-0.7% 	29.2% 	32.5%
*Estimated as of 1/23/2024
As Reported Research and Development Expense 	$ 	3,357 	3,070 	1,123 	640 	4,480 	3,710
% to Sales 	24.5% 	23.3% 	14.6% 	9.4% 	20.9% 	18.6%
Q4 QTD - Income Before Tax* and Research & Development Expense by Segment
Dollars in Millions
Innovative Medicine 	MedTech 	Unallocated 	Worldwide Total

-- 19 of 21 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022
Reported Income Before Tax by Segment From Continuing Operations $ 	18,246 	15,647 	4,669 	4,447 	(7,853) 	(735) 	15,062 	19,359
% to Sales 	33.3% 	29.8% 	15.4% 	16.2% 	-9.2% 	-0.9% 	17.7% 	24.2%
Intangible asset amortization expense 	2,983 	2,911 	1,549 	1,033 	- 	- 	4,532 	3,944
In-process research and development impairments 	206 	783 	107 	- 	- 	- 	313 	783
Litigation related 	(108) 	104 	190 	612 	7,070 	150 	7,152 	866
Loss/(gain) on securities 	362 	696 	(102) 	(6) 	381 	- 	641 	690
Restructuring related 	479 	63 	319 	309 	- 	- 	798 	372
Acquisition, integration and divestiture related 	175 	(104) 	164 	300 	- 	- 	339 	196
Medical Device Regulation 	- 	- 	311 	296 	- 	- 	311 	296
COVID-19 Vaccine related costs 	663 	1,474 	- 	- 	- 	- 	663 	1,474
Other 	- 	- 	- 	- 	- 	(7) 	- 	(7)
Adjusted Income Before Tax by Segment From Continuing Operations 	$ 	23,006 	21,574 	7,207 	6,991 	(402) 	(592) 	29,811 	27,973
% to Sales 	42.0% 	41.0% 	23.7% 	25.5% 	-0.5% 	-0.7% 	35.0% 	35.0%
*Estimated as of 1/23/2024
As Reported Research and Development Expense 	$ 	11,963 	11,642 	3,122 	2,493 	15,085 	14,135
% to Sales 	21.8% 	22.1% 	10.3% 	9.1% 	17.7% 	17.7%
Q4 YTD - Income Before Tax* and Research & Development Expense by Segment
Dollars in Millions
Innovative Medicine 	MedTech 	Unallocated 	Worldwide Total

-- 20 of 21 --

Fourth Quarter
Dec. 31, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Fourth Quarter
Dec. 31, 2023
Non-GAAP
Cost of products sold 	6,798	$ 	(1,131) 	(83) 	(42) 	(12) 	- 	- 	5,530
Selling, marketing and admin expenses 	5,810 	(8) 	5,802
Research and development expense 	4,480 	(16) 	(38) 	(1) 	4,425
Other (Income) / Expense 	(421) 	(17) 	(166) 	- 	(221) 	435 	3 	- 	(387)
In-process research and development impairments 	58 	(58) 	-
Restructuring 	56 	(56) 	-
Provision for taxes on income 	694 	175 	(134) 	13 	16 	30 	(191) 	16 	- 	56 	- 	675
Net Earnings from Continuing Operations 	4,132 	973 	300 	45 	123 	207 	(244) 	72 	10 	(56) 	- 	5,562
Fourth Quarter
Jan. 1, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Fourth Quarter
Jan. 1, 2023
Non-GAAP
Cost of products sold 	6,084	$ 	(977) 	(25) 	(33) 	(160) 	- 	- 	4,889
Selling, marketing and admin expenses 	5,339 	(9) 	5,330
Research and development expense 	3,710 	- 	(46) 	(114) 	3,550
Other (Income) / Expense 	795 	- 	(262) 	(19) 	(196) 	(6) 	(547) 	- 	(235)
In-process research and development impairments 	173 	(173) 	-
Restructuring 	75 	(75) 	-
Provision for taxes on income 	613 	148 	(36) 	40 	19 	5 	2 	17 	199 	43 	- 	1,050
Net Earnings from Continuing Operations 	3,227 	829 	298 	133 	100 	191 	4 	71 	622 	(43) 	- 	5,432
Twelve Months
Dec. 31, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Twelve Months
Dec. 31, 2023
Non-GAAP
Cost of products sold 	26,553	$ 	(4,511) 	(309) 	(133) 	(189) 	21,411
Selling, marketing and admin expenses 	21,512 	(29) 	- 	21,483
Research and development expense 	15,085 	(32) 	(149) 	(99) 	14,805
Other (Income) / Expense 	6,634 	(21) 	(7,152) 	- 	(307) 	(641) 	(375) 	- 	(1,862)
In-process research and development impairments 	313 	(313) 	- 	- 	- 	- 	-
Restructuring 	489 	(489) 	-
Provision for taxes on income 	1,736 	707 	1,505 	70 	157 	52 	(9) 	57 	155 	(28) 	- 	4,402
Net Earnings from Continuing Operations 	13,326 	3,825 	5,647 	243 	641 	287 	650 	254 	508 	28 	- 	25,409
Twelve Months
Jan. 1, 2023
GAAP
Intangible asset
amortization Litigation related
Restructuring
related
Medical Device
Regulation 	Other
Twelve Months
Jan. 1, 2023
Non-GAAP
Cost of products sold 	24,596	$ 	(3,944) 	(62) 	(109) 	(456) 	20,025
Selling, marketing and admin expenses 	20,246 	(28) 	20,218
Research and development expense 	14,135 	- 	(159) 	(304) 	13,672
Other (Income) / Expense 	810 	- 	(866) 	(35) 	(196) 	(690) 	(714) 	7 	(1,684)
In-process research and development impairments 	783 	(783) 	- 	-
Restructuring 	275 	(275) 	-
Provision for taxes on income 	2,989 	590 	(125) 	178 	66 	5 	166 	56 	360 	(106) 	(2) 	4,177
Net Earnings from Continuing Operations 	16,370 	3,354 	991 	605 	306 	191 	524 	240 	1,114 	106 	(5) 	23,796
In-process
research and
development
impairments
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
In-process
research and
development
impairments
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
Year to Date
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
In-process
research and
development
impairments
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related
In-process
research and
development
impairments
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
COVID-19 Vaccine
Related Costs
Tax legislation and
other tax related

-- 21 of 21 --